[{"data":1,"prerenderedAt":197},["ShallowReactive",2],{"media-slots-en":3,"guide-item-en-hsct-gvhd":61},{"about.hero":4,"about.video":6,"about.video-cover":8,"charity.hero":10,"contact.hero":12,"evidence.hero":14,"footer.qr-blood":16,"footer.qr-mini":18,"footer.qr-official":20,"footer.qr-solid":22,"guide.hero":24,"home.hero":26,"home.news-featured":28,"home.story-featured":30,"news.hero":32,"news.lead":34,"news.thumb":36,"stories.cover":41,"stories.hero":48,"stories.lead":50,"wiki.cat":52,"wiki.detail-hero":57,"wiki.hero":59},[5],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E5%85%B3%E4%BA%8E%E5%8D%9A%E5%8C%BB%E5%90%8C%E8%A1%8C_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[7],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002F%E9%A3%9E%E4%B9%A620260729-233252_compressed.mp4",[9],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002F%E9%A3%9E%E4%B9%A620260729-233252_frame1.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[11],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E5%85%AC%E7%9B%8A%E8%B5%84%E6%BA%90%E9%93%BE%E6%8E%A5_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[13],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F08\u002Fbde8f2354d29ffca7dcfe395ef4711b2.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[15],"https:\u002F\u002Fwww.yyhmedical.com\u002Fimages\u002Fevidence\u002Fhero.jpg",[17],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002Fqr-blood.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[19],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002Fqr-mini.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[21],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002Fqr-official.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[23],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002Fqr-solid.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[25],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E7%96%BE%E7%97%85%E7%9F%A5%E8%AF%86%E5%BA%93_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[27],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E9%A6%96%E9%A1%B5_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[29],"\u002Fimages\u002Fhome\u002Fnews-featured.jpg",[31],"\u002Fimages\u002Fhome\u002Fstory-featured.jpg",[33],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E6%82%A3%E5%8F%8B%E5%85%B3%E6%B3%A8_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[35],"\u002Fimages\u002Fnews\u002Flead.jpg",[37,38,39,40],"\u002Fimages\u002Fnews\u002Fn1.jpg","\u002Fimages\u002Fnews\u002Fn2.jpg","\u002Fimages\u002Fnews\u002Fn3.jpg","\u002Fimages\u002Fnews\u002Fn4.jpg",[42,43,44,45,46,47],"\u002Fimages\u002Fstories\u002Fs1.jpg","\u002Fimages\u002Fstories\u002Fs2.jpg","\u002Fimages\u002Fstories\u002Fs3.jpg","\u002Fimages\u002Fstories\u002Fs4.jpg","\u002Fimages\u002Fstories\u002Fs5.jpg","\u002Fimages\u002Fstories\u002Fs6.jpg",[49],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E6%82%A3%E8%80%85%E6%95%85%E4%BA%8B_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[51],"\u002Fimages\u002Fstories\u002Flead.jpg",[53,54,55,56],"\u002Fimages\u002Fwiki\u002Fcat-1.jpg","\u002Fimages\u002Fwiki\u002Fcat-2.jpg","\u002Fimages\u002Fwiki\u002Fcat-3.jpg","\u002Fimages\u002Fwiki\u002Fcat-4.jpg",[58],"\u002Fimages\u002Fwiki\u002Fdetail-hero.jpg",[60],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E6%8A%97%E7%99%8C%E7%99%BE%E7%A7%91_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",{"slug":62,"kind":63,"title":64,"summary":65,"cover":66,"contentHtml":67,"toc":68,"relatedQuestions":193,"ymyl":194,"hasAlternate":196,"updatedAt":87},"hsct-gvhd","manual","Hematopoietic Stem Cell Transplantation: Graft-versus-Host Disease","Learn about the causes, classification, high-risk factors, symptoms, and treatment of graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation, and ensure effective post-transplant management.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F10\u002Fb13cf82314c2fc5d619d5e38bb7c86e2.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","",[69,88,106,121,139,157,175],{"key":70,"title":71,"html":72,"relatedQuestions":73,"hotSummary":86,"updatedAt":87},"what-is-gvhd","What Is Graft-versus-Host Disease (GVHD)?","\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Overview: Graft-versus-host disease (GVHD) is one of the important complications that require particular attention after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients and families sometimes refer to it as a “rejection reaction,” although GVHD specifically involves donor immune cells attacking the recipient’s tissues. \u003C\u002Fspan>\u003Cspan style=\"font-size: 15px;\">During allo-HSCT, a patient receives healthy blood-forming stem cells from a donor. Because donor and recipient differ immunologically and genetically, immune cells originating from the donor may recognize the patient’s normal tissues as foreign. The resulting immune attack can injure the skin, intestines, liver, lungs, and other organs. \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Why can GVHD develop after transplantation?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Allogeneic HSCT is an important treatment option for selected blood cancers and other hematologic disorders. Unlike autologous transplantation, which uses a patient’s own cells, allogeneic transplantation uses stem cells from another person. After infusion, these cells gradually establish a new blood-forming and immune system in the recipient.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">However, donor immune cells entering the patient’s body may not fully adapt to their new environment because of immunogenetic differences. Immune cells normally identify and eliminate abnormal cells, but in this setting they can mistakenly regard normal recipient tissues as foreign and attack them. When the immune reaction causes significant tissue injury, GVHD develops. The skin, gastrointestinal tract, liver, and lungs are among the organs that may be affected.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How can GVHD affect the transplant outcome?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">GVHD is a major complication to prevent and manage after allo-HSCT. Severe disease can reduce quality of life, increase infection risk, and even affect survival. Yet donor immunity also has a potentially beneficial role: donor immune cells may recognize and attack residual leukemia cells, a response called the graft-versus-leukemia (GVL) effect.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">For this reason, transplant care does not simply aim to eliminate every immune response. Instead, clinicians seek to limit harmful attacks on normal tissues while preserving beneficial anti-cancer activity where possible.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Which organs are commonly affected?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong>Skin:\u003C\u002Fstrong> Rash, redness, and itching may occur. Skin is among the most frequently affected organs.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong>Intestines:\u003C\u002Fstrong> Nausea, vomiting, and diarrhea may occur; severe intestinal involvement can cause blood in the stool.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong>Liver:\u003C\u002Fstrong> GVHD may cause abnormal liver-function tests, including increased bilirubin.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong>Other organs:\u003C\u002Fstrong> Chronic GVHD can also affect the mouth, lungs, gastrointestinal tract, muscles, and joints, potentially influencing everyday life over the long term.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003C\u002Fspan>\u003Cstrong>Will everyone develop GVHD?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">No. Although GVHD is a recognized complication of allo-HSCT, it does not occur in every patient. Risk depends on multiple factors, including the degree of donor–recipient HLA matching, donor and recipient characteristics, the transplant regimen, and infections. Advances in donor selection, conditioning regimens, and supportive transplant care have improved prevention and management. The transplant team selects preventive and treatment strategies based on each patient’s situation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Does developing GVHD mean the transplant has failed?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">No. GVHD is not the same as transplant failure. In some situations, mild GVHD may occur alongside a stronger GVL response and may be associated with a lower relapse risk. However, excessive GVHD can seriously damage organs and needs prompt treatment. The goal remains to control harmful immune injury while retaining useful anti-disease effects where possible.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How can patients help prevent and recognize GVHD?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Long-term follow-up after transplantation is essential. Attend scheduled appointments and pay attention to new changes in your health. Contact the transplant team promptly if you notice a new rash, redness, or itching; persistent nausea, vomiting, or diarrhea; pronounced dryness of the eyes or mouth; unexplained fatigue; or breathing symptoms. Early identification, assessment, and appropriate treatment can reduce the risk of progression.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">GVHD develops when donor immune cells recognize and attack normal recipient tissues after allo-HSCT. It can damage the skin, intestines, liver, lungs, and other organs. Some donor immune activity may also contribute to the GVL effect, but severe GVHD is harmful. Prevention, early recognition, and appropriate treatment can support safer recovery.\u003C\u002Fspan>\u003C\u002Fp>",[74,77,80,83],{"question":75,"answer":76},"Q1: Does GVHD mean my transplant has failed?","No. GVHD is a recognized complication of allo-HSCT, not proof of failure. Mild GVHD can sometimes accompany an anti-cancer immune response, whereas severe GVHD requires active treatment.",{"question":78,"answer":79},"Q2: Why would donor cells attack my own body?","After entering the recipient, donor immune cells can recognize immunologic differences between donor and recipient. If that response becomes excessive, they may attack the patient’s normal tissues.",{"question":81,"answer":82},"Q3: Can GVHD be prevented?","Its risk can be reduced. The transplant team uses measures such as appropriate donor selection, transplant-regimen planning, and preventive medication.",{"question":84,"answer":85},"Q4: Can GVHD still be treated after it develops?","Yes. Depending on severity and the organs involved, clinicians may use immunosuppressive medication, supportive care, and other individualized treatments.","GVHD develops when donor immune cells recognize and attack normal recipient tissues after allo-HSCT. It can damage the skin, intestines, liver, lungs, and other organs.","2026-10-10",{"key":89,"title":90,"html":91,"relatedQuestions":92,"hotSummary":105,"updatedAt":87},"types-of-gvhd","How Is Graft-versus-Host Disease Classified?","\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Overview: GVHD is an immune-related complication of allo-HSCT in which donor immune cells may damage recipient tissues, including the skin, intestines, and liver. Clinicians generally distinguish acute GVHD (aGVHD) from chronic GVHD (cGVHD), considering timing, clinical features, and patterns of organ involvement. The two types differ in presentation and management. Understanding these distinctions helps patients recognize changes and participate in follow-up care.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Why does GVHD need to be classified?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Not all GVHD is the same. Its onset, immune features, and affected organs vary. Classification helps clinicians understand the pattern of disease and choose appropriate treatment. Acute and chronic GVHD are the two principal clinical categories.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What is acute GVHD?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Acute GVHD often develops relatively early after allo-HSCT. Traditionally, GVHD occurring within the first 100 days was called acute GVHD. It is caused by donor-derived immune cells attacking recipient tissues and most commonly involves the skin, intestines, and liver.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">Acute GVHD affecting the skin\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Skin is one of the most common sites of acute GVHD. Patients may develop a rash, redness, or itching; severe involvement can cause peeling or shedding of skin. Any new skin changes after transplant should be reported so the transplant team can determine whether GVHD is responsible.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">Acute GVHD affecting the intestines\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Intestinal involvement may cause diarrhea, abdominal pain, nausea, or vomiting; severe cases may include blood in the stool. Prompt assessment matters because ongoing intestinal injury can impair nutrition and increase infection risk.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">Acute GVHD affecting the liver\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Liver involvement may cause no obvious symptoms. Instead, blood tests may reveal increased bilirubin or other abnormal liver-function results. This is one reason routine post-transplant testing is important.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What is chronic GVHD?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Chronic GVHD usually appears later after transplantation. Compared with acute GVHD, the immune injury can be more complex and the symptoms more varied. It may affect the skin, mouth, eyes, lungs, gastrointestinal tract, liver, muscles, and joints. Some manifestations resemble autoimmune disorders, such as skin thickening or tightening and dry eyes or mouth.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How do acute and chronic GVHD differ?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Acute GVHD more commonly occurs early and primarily affects the skin, intestines, and liver. Chronic GVHD generally appears later, can affect a broader range of organs, and may have more complex symptoms. However, modern classification does not rely on time alone: chronic-type features can appear earlier, and some patients have overlapping acute and chronic manifestations. Doctors consider symptoms and test results together.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How is GVHD severity assessed?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">In addition to determining whether GVHD is acute or chronic, clinicians assess its severity. This depends on which organs are involved, how extensive the damage is, how severe the symptoms are, and the patient’s overall condition. Mild skin involvement and severe intestinal GVHD can have very different consequences. Accurate assessment guides treatment selection.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Why does classification matter for treatment?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Acute GVHD management commonly focuses on controlling abnormal inflammation, limiting organ damage, and preventing infection. Chronic GVHD often requires longer-term, organ-specific care, tailored to severity and symptoms. Identifying the type and extent of GVHD is therefore an important step in treatment planning.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">GVHD is broadly divided into acute and chronic forms. Acute disease commonly affects the skin, intestines, and liver early after transplant, while chronic disease often occurs later and may affect many systems. Accurate classification and severity assessment support appropriate treatment; regular follow-up helps identify changes early.\u003C\u002Fspan>\u003C\u002Fp>",[93,96,99,102],{"question":94,"answer":95},"Q1: Are acute and chronic GVHD the only two types?","They are the two main clinical categories, but clinicians also consider timing, symptoms, and other features to make a more detailed assessment.",{"question":97,"answer":98},"Q2: Does acute GVHD always turn into chronic GVHD?","No. They have different clinical features, and some patients who develop acute GVHD never develop chronic GVHD.",{"question":100,"answer":101},"Q3: Is chronic GVHD always more serious than acute GVHD?","No. Impact depends on the organs involved and disease severity. Acute GVHD can rapidly damage vital organs, while chronic GVHD can substantially affect long-term quality of life.",{"question":103,"answer":104},"Q4: If I have no symptoms, does that mean I do not have GVHD?","Not necessarily. Some changes are detected through examinations or laboratory testing rather than obvious symptoms. Regular follow-up remains important.","GVHD is broadly divided into acute and chronic forms. Acute disease commonly affects the skin, intestines, and liver early after transplant, while chronic disease often occurs later and may affect many systems.",{"key":107,"title":108,"html":109,"relatedQuestions":110,"hotSummary":120,"updatedAt":87},"acute-gvhd-risk-factors","What Are the Risk Factors for Acute GVHD?","\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Overview: Acute graft-versus-host disease (aGVHD) is an immune-related complication of allo-HSCT. Donor immune cells may recognize and attack normal recipient tissues, potentially injuring the skin, intestines, and liver. Not every patient develops aGVHD. Risk is influenced by several factors, including donor–recipient HLA compatibility, donor and recipient age, disease status before transplant, prior transfusions, and infections. Recognizing risk factors helps the transplant team plan prevention and monitoring.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Why are some patients more likely to develop acute GVHD?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">After allo-HSCT, donor stem cells help establish a new blood-forming and immune system. At the same time, donor immune cells may recognize differences in recipient tissue antigens and mount an immune attack. Acute GVHD reflects a disruption of the immune balance between donor cells and the recipient. No single factor determines whether it will occur; clinicians evaluate multiple donor, patient, and treatment-related factors together.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Which factors can increase the risk?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp>\u003Cstrong style=\"font-size: 15px;\">Donor–recipient HLA compatibility\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Human leukocyte antigens (HLA) are important markers of immune compatibility between donor and recipient. In general, closer HLA matching is associated with a lower risk of immune incompatibility after transplant. Greater HLA differences may make it easier for donor immune cells to recognize recipient tissues as different, potentially increasing GVHD risk. HLA testing and donor selection are therefore important before allo-HSCT.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">Donor and recipient age\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Age is another consideration. Immune-cell function and activity may change with donor age, potentially influencing post-transplant immune reactions. Older recipients may also have more underlying medical conditions and reduced capacity for recovery or immune regulation. The transplant team considers these factors when evaluating complication risk.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">Transfusions before transplantation\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Some patients have received multiple blood transfusions before transplant. Transfusions may expose them to immune cells or antigens from different sources, which could influence subsequent immune responses. The transplant team therefore reviews prior transfusion history as part of its overall risk assessment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">Infection-related factors\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Infections before or after transplantation may affect GVHD risk. During periods of impaired immunity, viral infections and other infections may further disturb immune balance. Infection surveillance, prevention, and appropriate management are consequently important throughout transplantation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Is acute GVHD unavoidable?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">No. Although some factors increase risk, modern transplantation includes established GVHD prevention and management measures. Clinicians can reduce risk through appropriate donor selection, thoughtful transplant-regimen design, prophylactic medications, and close post-transplant monitoring.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">It is also important to understand the relationship between GVHD and donor anti-leukemia immunity. Some mild GVHD may occur alongside a graft-versus-leukemia (GVL) effect, which may help lower relapse risk. The goal is not to eliminate all donor immune activity, but to control harmful reactions while preserving beneficial effects where possible.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How can acute GVHD be detected early?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Acute GVHD often appears in the early period after transplant, making close observation important. Report any new rash, skin redness or itching, persistent diarrhea or abdominal pain, nausea or vomiting, or abnormal liver tests to the transplant team. Early assessment and appropriate treatment can help prevent worsening tissue injury.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Acute GVHD risk is related to immune differences between donor and recipient and may be influenced by HLA compatibility, age, prior transfusions, and infection status. Careful assessment before transplantation, close monitoring afterward, and prompt management of changes can help reduce its impact.\u003C\u002Fspan>\u003C\u002Fp>",[111,114,117],{"question":112,"answer":113},"Q1: Does an incomplete HLA match mean I will definitely develop GVHD?","No. HLA compatibility affects risk but is not the only factor. The transplant team also considers the disease, donor characteristics, and transplant regimen.",{"question":115,"answer":116},"Q2: Does acute GVHD mean my transplant has failed?","No. Acute GVHD is a recognized complication, not proof of transplant failure. Mild disease may coexist with an anti-disease immune effect, but early recognition and appropriate management remain essential.",{"question":118,"answer":119},"Q3: How can the risk of acute GVHD be reduced?","Measures include optimizing donor selection, planning an appropriate transplant regimen, using preventive medications, and closely monitoring the patient after transplantation.","Acute GVHD risk is related to immune differences between donor and recipient and may be influenced by HLA compatibility, age, prior transfusions, and infection status.",{"key":122,"title":123,"html":124,"relatedQuestions":125,"hotSummary":138,"updatedAt":87},"gvhd-treatment","How Is Graft-versus-Host Disease Treated?","\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Overview: GVHD is an important complication of allo-HSCT. Donor immune cells can attack recipient tissues and affect the skin, intestines, liver, lungs, and other organs, potentially disrupting recovery. Treatment is individualized according to whether GVHD is acute or chronic, its severity, and the organs involved. Corticosteroids remain an important foundation of treatment; other immunosuppressive drugs, targeted therapies, and supportive care may also be used. The aim is to control harmful immune activity and organ injury while retaining useful donor anti-tumor immunity where possible.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Why is timely treatment important?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Donor immune cells help establish a new immune system after transplantation, but they can sometimes attack normal tissues. Without adequate control, ongoing GVHD may cause marked skin inflammation, persistent diarrhea and impaired nutrient absorption, abnormal liver function, or chronic lung injury. Suspected GVHD therefore needs early medical assessment and appropriate treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Treatment does not simply mean suppressing every immune response. Donor immune cells can also contribute to the graft-versus-leukemia (GVL) effect by attacking residual disease. Clinicians aim to control damaging immune activity while preserving beneficial anti-disease activity where feasible.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What are the main treatments for GVHD?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp>\u003Cstrong style=\"font-size: 15px;\">Corticosteroid treatment\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Corticosteroids are important medications for acute GVHD and some cases of chronic GVHD. Drugs such as methylprednisolone have anti-inflammatory and immune-modulating effects. They can reduce abnormal immune responses and lessen attacks by donor immune cells on recipient tissues. Symptoms may improve with appropriate treatment in some patients with mild or moderate GVHD.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">However, prolonged corticosteroid use can cause problems such as increased infection risk, changes in blood glucose, and effects on bone health. Doctors therefore continually evaluate treatment response and potential adverse effects.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">Immunosuppressive treatment\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Because GVHD is immune-mediated, immunosuppressive and immune-modulating therapies are important parts of care. Depending on the patient, doctors may use different medications to reduce excessive immune activity and tissue damage. They must balance control of GVHD-related organ injury against the risks of excessive immunosuppression, including infection and possible effects on anti-disease immunity.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">Other medications and newer approaches\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">If standard treatment does not provide an adequate response, or GVHD is refractory, the medical team may consider other approaches. Research continues to introduce new drugs and strategies, including therapies targeting particular immune pathways. The choice depends on GVHD type, severity, previous treatment response, and the patient’s overall condition.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">Supportive care\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Comprehensive supportive care is needed alongside immune-directed treatment. Intestinal GVHD may require nutritional support and careful management of fluids and electrolytes. Patients at higher infection risk need prevention, surveillance, and treatment of infections. Skin and oral involvement may require dedicated local care. Supportive measures are important throughout treatment and recovery.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Is treatment the same for acute and chronic GVHD?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Not entirely. Acute and chronic GVHD differ in their mechanisms, manifestations, and treatment priorities. Acute GVHD management often focuses on rapidly controlling inflammation and preventing injury to the skin, intestines, and liver. Chronic GVHD can involve multiple systems and may require prolonged treatment adjusted to the affected organs and symptoms. The team first assesses GVHD type and severity before selecting an approach.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What should patients pay attention to during treatment?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">GVHD treatment can take considerable time. Take medications as prescribed; do not independently change doses or stop immunosuppressive drugs, as sudden discontinuation may alter disease control. Pay attention to infection prevention because both GVHD and its treatments can impair immune defenses. Report fever, cough, worsening diarrhea, or other new symptoms promptly. Attend follow-up appointments so clinicians can assess symptoms, laboratory findings, and organ function and adjust treatment as needed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How effective is treatment?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Outcomes vary with GVHD type, severity, affected organs, how early it is recognized and treated, and the patient’s overall health. Some patients achieve good symptom control with appropriate treatment, while severe or refractory GVHD may be more complicated and require long-term management. Advances in transplantation and GVHD therapies continue to improve clinical understanding and management.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">GVHD treatment must be individualized. Corticosteroids, other immunosuppressive medications, newer therapies, and supportive care may all have a role. The aim is to reduce abnormal immune injury and organ damage without unnecessarily compromising the beneficial anti-disease activity of donor immune cells.\u003C\u002Fspan>\u003C\u002Fp>",[126,129,132,135],{"question":127,"answer":128},"Q1: Can GVHD be cured?","Outcomes differ. Some patients achieve good control after treatment, while others need long-term management. The outlook depends on GVHD type, severity, and response to therapy.",{"question":130,"answer":131},"Q2: Does treating GVHD mean my immunity must be suppressed indefinitely?","No. Clinicians adjust treatment intensity according to the patient’s condition, balancing GVHD control with preservation and recovery of immune function.",{"question":133,"answer":134},"Q3: Are corticosteroids the only treatment for GVHD?","No. They are an important option, but other immunosuppressive medications, targeted treatments, and supportive care may also be used.",{"question":136,"answer":137},"Q4: Why are infections more likely during GVHD treatment?","GVHD itself disrupts immune balance, and immunosuppressive medications can reduce the body’s ability to resist infections. Prevention and close monitoring are therefore essential.","Treatment is individualized according to whether GVHD is acute or chronic, its severity, and the organs involved.",{"key":140,"title":141,"html":142,"relatedQuestions":143,"hotSummary":156,"updatedAt":87},"gvhd-and-graft-versus-leukemia-effect","Is Developing GVHD Always a Bad Sign?","\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Overview: GVHD is an immune-related complication of allo-HSCT that occurs when donor immune cells recognize and attack the recipient’s normal tissues. The skin, intestines, liver, and other organs may be injured. Hearing that GVHD has developed can make patients worry that transplantation has failed. However, GVHD is sometimes described as a “double-edged sword”: severe disease can interfere with recovery, while donor immune activity may also produce a graft-versus-leukemia or graft-versus-tumor (GVL\u002FGVT) effect against residual malignant cells. Clinical care aims to limit harmful GVHD, not encourage it, while preserving useful anti-disease immunity where possible.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Why is GVHD called a double-edged sword?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">The purpose of allo-HSCT is to establish a new blood-forming and immune system using healthy donor stem cells. After transplantation, donor-derived immune cells become active in the recipient. On one hand, they can recognize and attack remaining disease cells. On the other, immunologic differences between donor and recipient can cause them to identify normal recipient tissues as foreign, leading to GVHD.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">GVHD is therefore not simply “good” or “bad.” Excessive immune reactions can damage the skin, intestines, liver, and other organs, reduce quality of life, and even threaten survival. Conversely, donor immune activity is part of the anti-disease effect of allogeneic transplantation. The challenge is to balance these effects.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How might donor immunity help control disease?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Patients sometimes ask how an immune reaction that injures their tissues could also have a benefit. Donor immune cells may react to both normal recipient cells and residual disease cells. When they recognize and attack remaining leukemia or other abnormal cells, this is called the GVL or GVT effect.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">This donor immune activity is one mechanism through which allo-HSCT may provide long-term control of certain blood disorders. For some patients with leukemia, it may help lower the risk of relapse after transplantation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Does more severe GVHD mean stronger anti-cancer treatment?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">No. More obvious or severe GVHD does not automatically mean better disease control. Severe GVHD reflects damaging immune activity against normal tissues and can increase the risks of infection and organ dysfunction. The ideal outcome is not progressively stronger GVHD, but an acceptable balance between beneficial anti-disease immunity and protection of the patient’s organs. Doctors assess and manage GVHD as the patient’s condition changes.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Does having no GVHD mean the transplant is not working?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">No. Some patients have no clinically obvious GVHD and still achieve good disease control. Transplant outcomes depend on multiple factors: disease status before transplantation, donor–recipient compatibility, the transplant regimen, management of infections and other complications, and the patient’s recovery. GVHD alone cannot establish whether a transplant has succeeded.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What should patients do if GVHD develops?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Patients and families need not assume the worst when GVHD-related symptoms appear, but they should seek timely assessment. Modern transplant care includes established approaches to prevention, diagnosis, and treatment. Report new skin rash, persistent diarrhea, abnormal liver tests, or dryness of the eyes or mouth to the transplant team. Treatment is chosen according to the type and severity of GVHD and the organs involved. Early identification and appropriate care can reduce harm.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How should patients understand GVHD in relation to transplant success?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">GVHD is neither proof of transplant failure nor a desirable sign in itself. It is an immune reaction that must be managed because it may cause tissue injury even when donor immunity is helping control disease. Modern transplantation aims to regulate immunity carefully so that the patient is protected while the therapeutic potential of donor cells is used effectively.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">GVHD is a complex immune response after allo-HSCT. It can damage normal tissues and require treatment, while some donor immune activity may contribute to the GVL\u002FGVT effect. More severe GVHD is not better. The priority is safe, individualized control of harmful immune responses while maintaining beneficial disease control when possible.\u003C\u002Fspan>\u003C\u002Fp>",[144,147,150,153],{"question":145,"answer":146},"Q1: Does GVHD mean the transplant has failed?","No. Transplant success must be assessed using disease status, blood-forming recovery, and subsequent follow-up results, not GVHD alone.",{"question":148,"answer":149},"Q2: Does more severe GVHD mean better anti-cancer effects?","No. Some donor immune activity may help control disease, but severe GVHD can cause significant organ damage. The aim is to balance benefit and harm.",{"question":151,"answer":152},"Q3: If I have no GVHD, does that mean donor cells are not working?","No. Patients without obvious GVHD may still benefit from transplantation. Many factors determine the outcome.",{"question":154,"answer":155},"Q4: Can GVHD be treated while recovery continues?","Yes. Doctors select treatment based on GVHD severity and the organs affected to control immune-related injury.","GVHD is a complex immune response after allo-HSCT. It can damage normal tissues and require treatment, while some donor immune activity may contribute to the GVL\u002FGVT effect.",{"key":158,"title":159,"html":160,"relatedQuestions":161,"hotSummary":174,"updatedAt":87},"intestinal-gvhd-symptoms","What Are the Symptoms of Intestinal GVHD?","\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Overview: Intestinal graft-versus-host disease, often called “gut GVHD,” is a possible manifestation of GVHD after allo-HSCT. It occurs when donor immune cells attack intestinal tissues and damage the gut lining. Symptoms may include diarrhea, abdominal pain, nausea, and vomiting. Severity varies: some patients have mild diarrhea, while others develop persistent high-volume diarrhea, blood in the stool, or impaired nutrient absorption. New gastrointestinal symptoms after transplant should be reported to the transplant team for assessment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What is intestinal GVHD?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Patients with diarrhea after transplantation may wonder whether they ate something unsuitable, developed an infection, or are experiencing GVHD. In fact, diarrhea after transplant has several possible causes and is not always GVHD.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Intestinal GVHD refers to inflammation and injury of the intestines caused by donor immune cells recognizing and attacking recipient intestinal tissues after allo-HSCT. Injury to the intestinal lining can produce a range of digestive symptoms. To determine whether GVHD is responsible, doctors consider the timing after transplant, symptom pattern, infection testing, and any additional investigations needed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What are the common symptoms?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Ch3 style=\"margin-top: 13px;margin-bottom: 0;break-after: avoid;color: rgb(31, 65, 90);\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong>Diarrhea\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh3>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Diarrhea is one of the common manifestations of intestinal GVHD. Patients may notice more frequent bowel movements, looser stools, or diarrhea that persists over time. Because post-transplant diarrhea can have different causes, it must be interpreted in the context of the transplant and the patient’s overall condition. Persistent or worsening diarrhea should be reported promptly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">Abdominal pain and discomfort\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Some patients experience abdominal pain, bloating, or general discomfort. These symptoms may result from local inflammation when donor immune cells injure the intestinal lining. Abdominal pain accompanied by ongoing diarrhea, fever, or other concerning symptoms needs prompt medical evaluation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">Nausea, vomiting, and reduced appetite\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">When GVHD affects the gastrointestinal tract, patients may feel nauseated, vomit, eat less, or lose their appetite. Symptoms that continue over time can reduce nutritional intake, making nutritional support and symptom management important.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">Blood in the stool or severe digestive symptoms\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">In more serious intestinal GVHD, substantial damage to the intestinal lining can cause bleeding and blood in the stool. Blood in the stool, marked abdominal pain, or large-volume diarrhea requires prompt contact with the medical team because severe intestinal injury may interfere with overall recovery.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How is intestinal GVHD different from ordinary diarrhea?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Not every episode of diarrhea after transplantation indicates intestinal GVHD. Other possible causes include infections, medication side effects, diet-related factors, and changes in intestinal function. A single episode of diarrhea cannot establish the diagnosis. The team considers whether the patient received allo-HSCT, when diarrhea began, symptom severity, infection-related test results, and any additional examinations needed to identify the cause.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How is intestinal GVHD managed?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">When intestinal GVHD is suspected, treatment is individualized according to symptom severity and overall health. Main priorities include controlling the abnormal immune response, reducing intestinal injury, maintaining nutrition, and addressing infection risk. Some patients may need immune-modulating treatment, such as corticosteroids. Supportive care is also essential and may include replacement of fluids and electrolytes, changes to nutritional support, and prevention or treatment of infections. The exact plan depends on GVHD severity and the patient’s condition.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>When should patients seek medical advice?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Any new digestive changes after HSCT deserve attention. Contact the transplant team if bowel movements become substantially more frequent, abdominal pain persists, nausea or vomiting worsens, eating becomes difficult, or blood appears in the stool. Early assessment and appropriate management can reduce the risk of serious complications.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Intestinal GVHD can cause diarrhea, abdominal pain, nausea, vomiting, loss of appetite, and, in severe cases, blood in the stool. However, digestive symptoms after transplant are not always caused by GVHD. Prompt recognition, clinical assessment, and appropriate treatment can help limit its impact.\u003C\u002Fspan>\u003C\u002Fp>",[162,165,168,171],{"question":163,"answer":164},"Q1: Does diarrhea after transplant always mean intestinal GVHD?","No. Infection, medication effects, and intestinal GVHD are among several possible causes. A clinician must assess the individual circumstances.",{"question":166,"answer":167},"Q2: Is intestinal GVHD always severe?","No. Severity ranges from mild symptoms to substantial gastrointestinal injury. Early recognition and appropriate treatment are important.",{"question":169,"answer":170},"Q3: Can recovery continue after intestinal GVHD develops?","Yes. The team can treat and manage symptoms according to the patient’s condition to support continued post-transplant recovery.",{"question":172,"answer":173},"Q4: How can the effects of intestinal GVHD be reduced?","Measures include optimizing the transplant plan, GVHD prevention, early recognition, and appropriate treatment. Attend follow-up visits and report changes promptly.","Intestinal GVHD can cause diarrhea, abdominal pain, nausea, vomiting, loss of appetite, and, in severe cases, blood in the stool. However, digestive symptoms after transplant are not always caused by GVHD. ",{"key":176,"title":177,"html":178,"relatedQuestions":179,"hotSummary":192,"updatedAt":87},"chronic-pulmonary-gvhd-symptoms","What Are the Symptoms of Chronic Pulmonary GVHD?","\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Overview: Chronic pulmonary graft-versus-host disease refers to lung involvement in chronic GVHD after allo-HSCT. It is an important complication to watch for after transplantation. Persistent donor immune injury may affect lung tissue and airways, leading to cough, shortness of breath, and reduced exercise tolerance. Onset can be gradual and early symptoms subtle, making routine follow-up and pulmonary function testing particularly important. Early recognition and intervention may help slow deterioration and improve quality of life.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What is chronic pulmonary GVHD?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">When patients hear the term “lung GVHD,” they may wonder whether it means a lung infection or transplant failure. In fact, it usually describes chronic GVHD involving the lungs. After allo-HSCT, donor immune cells help build a new immune system, but immunologic differences may also cause these cells to attack recipient tissues. If this injury affects lung tissue and airways, chronic pulmonary GVHD may develop.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What symptoms can occur?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Symptoms can resemble common respiratory conditions, so they may be overlooked.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">Cough\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Persistent coughing is one possible symptom, often presenting as a dry cough. For some people, it becomes more noticeable with activity or exposure to cold air. An unexplained cough that lasts after transplantation should be reported so the medical team can investigate the cause.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">Breathlessness and reduced exercise tolerance\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">As lung involvement increases, patients may become short of breath during activity, tire more easily while climbing stairs or exercising, or feel that breathing is less comfortable. Early changes may only be noticeable during exercise, then become more pronounced as the condition progresses. Patients should not wait until severe breathing difficulty develops before seeking assessment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">Chest tightness or breathing discomfort\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Some patients experience chest tightness or a sensation that they cannot breathe comfortably. These symptoms are not specific to pulmonary GVHD. Clinicians consider transplant history, changes in symptoms, pulmonary function tests, and other findings to determine the cause.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Why is chronic pulmonary GVHD important?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Lung involvement can affect breathing and the ability to carry out everyday activities, with consequences for long-term quality of life. Because early symptoms can be subtle, patients may assume they are simply less fit than usual or still weak after transplant. However, persistent respiratory symptoms after transplantation warrant attention. Regular pulmonary function testing and follow-up can help clinicians identify changes earlier and respond appropriately.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How is chronic pulmonary GVHD assessed?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">A diagnosis is not based on cough or breathlessness alone. Doctors consider whether the patient has undergone allo-HSCT, whether other features of chronic GVHD are present, how respiratory symptoms have changed, and the results of pulmonary function tests. Imaging or other investigations may be needed. Pulmonary function testing is particularly useful for assessing post-transplant lung health. Repeated measurements can help show whether function is being affected and how it changes over time.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What should patients pay attention to?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Ongoing self-care and follow-up are important after HSCT. Attend appointments and complete pulmonary function assessments as advised. Report persistent cough, significant breathlessness during activity, worsening breathing difficulty, or reduced exercise tolerance. Infection prevention also matters because immune function may remain altered after transplant, and respiratory infections can further affect the lungs.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Can chronic pulmonary GVHD be treated?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Yes. Treatment is individualized based on the degree of lung involvement, the type of GVHD, and the patient’s overall condition. Main goals include controlling abnormal immune responses, slowing the decline in lung function, and improving quality of life. Because pulmonary GVHD may require long-term care, patients and clinicians need to work together on ongoing management.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Chronic pulmonary GVHD is a manifestation of chronic GVHD affecting the lungs and may cause cough, shortness of breath, and reduced exercise tolerance. Symptoms can be subtle early on. Regular follow-up, pulmonary function testing, timely assessment of respiratory symptoms, appropriate treatment, and long-term monitoring are important for protecting lung function and quality of life.\u003C\u002Fspan>\u003C\u002Fp>",[180,183,186,189],{"question":181,"answer":182},"Q1: Does coughing after transplant always mean chronic pulmonary GVHD?","No. Infection, medication effects, and other respiratory problems may also cause cough. The medical team needs to evaluate the cause.",{"question":184,"answer":185},"Q2: Can chronic pulmonary GVHD affect life expectancy?","Its impact varies with how early it is detected, disease severity, and treatment. Early recognition and appropriate management may improve disease control.",{"question":187,"answer":188},"Q3: Do I still need lung-function testing if I have no obvious symptoms?","Yes. Early pulmonary GVHD may have few or no noticeable symptoms, so regular follow-up and pulmonary function monitoring remain important.",{"question":190,"answer":191},"Q4: Can lung function return to normal after treatment?","Recovery differs among patients. Some improve with treatment, while others require long-term management. The outlook depends on disease severity and response to treatment.","Chronic pulmonary GVHD is a manifestation of chronic GVHD affecting the lungs and may cause cough, shortness of breath, and reduced exercise tolerance. Symptoms can be subtle early on.",[],{"author":67,"reviewedBy":67,"lastReviewed":67,"datePublished":67,"citations":195,"disclaimer":67},[],false,1792294304947]